Literature DB >> 11507192

DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

J W Hooper1, D M Custer, E Thompson, C S Schmaljohn.   

Abstract

Four hantaviruses-Hantaan virus (HTNV), Seoul virus (SEOV), Dobrava virus (DOBV) and Puumala virus-are known to cause hemorrhagic fever with renal syndrome (HFRS) in Europe and Asia. HTNV causes the most severe form of HFRS (5 to 15% case-fatality rate) and afflicts tens of thousands of people annually. Previously, we demonstrated that DNA vaccination with a plasmid expressing the SEOV M gene elicited neutralizing antibodies and protected hamsters against infection with SEOV and HTNV. Here, we report the construction and evaluation of a DNA vaccine that expresses the HTNV M gene products, G1 and G2. DNA vaccination of hamsters with the HTNV M gene conferred sterile protection against infection with HTNV, SEOV, and DOBV. DNA vaccination of rhesus monkeys with either the SEOV or HTNV M gene elicited high levels of neutralizing antibodies. These are the first immunogenicity data for hantavirus DNA vaccines in nonhuman primates. Because a neutralizing antibody response is considered a surrogate marker for protective immunity in humans, our protection data in hamsters combined with the immunogenicity data in monkeys suggest that hantavirus M gene-based DNA vaccines could protect humans against the most severe forms of HFRS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507192      PMCID: PMC115092          DOI: 10.1128/jvi.75.18.8469-8477.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice.

Authors:  M Bharadwaj; C R Lyons; I A Wortman; B Hjelle
Journal:  Vaccine       Date:  1999-07-16       Impact factor: 3.641

Review 2.  Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome.

Authors:  C J Peters; G L Simpson; H Levy
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

3.  Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters.

Authors:  K I Kamrud; J W Hooper; F Elgh; C S Schmaljohn
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

4.  Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: evidence of highly cross-neutralizing antibody responses in early patient sera.

Authors:  A Lundkvist; M Hukic; J Hörling; M Gilljam; S Nichol; B Niklasson
Journal:  J Med Virol       Date:  1997-09       Impact factor: 2.327

5.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Investigation on inactivated epidemic hemorrhagic fever tissue culture vaccine in humans.

Authors:  Z Y Zhu; H Y Tang; Y J Li; J Q Weng; Y X Yu; R F Zeng
Journal:  Chin Med J (Engl)       Date:  1994-03       Impact factor: 2.628

7.  Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes.

Authors:  F Elgh; A Lundkvist; O A Alexeyev; H Stenlund; T Avsic-Zupanc; B Hjelle; H W Lee; K J Smith; R Vainionpää; D Wiger; G Wadell; P Juto
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

8.  DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection.

Authors:  J W Hooper; K I Kamrud; F Elgh; D Custer; C S Schmaljohn
Journal:  Virology       Date:  1999-03-15       Impact factor: 3.616

Review 9.  Hantaviruses: a global disease problem.

Authors:  C Schmaljohn; B Hjelle
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

10.  A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus.

Authors:  Y K Chu; G B Jennings; C S Schmaljohn
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more
  40 in total

1.  In vivo kinetics and biodistribution of a Hantaan virus DNA vaccine after intramuscular injection in mice.

Authors:  Si Wang; Qing Nie; Lan-yan Zheng; Jun Hu; En-jie Luo
Journal:  Virol Sin       Date:  2010-06-06       Impact factor: 4.327

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

3.  Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.

Authors:  Sylvia Rothenberger; Christian Widmann; Stefan Kunz; Giulia Torriani; Evgeniya Trofimenko; Jennifer Mayor; Chiara Fedeli; Hector Moreno; Sébastien Michel; Mathieu Heulot; Nadja Chevalier; Gert Zimmer; Neeta Shrestha; Philippe Plattet; Olivier Engler
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Protocadherin-1 is essential for cell entry by New World hantaviruses.

Authors:  Rohit K Jangra; Andrew S Herbert; Rong Li; Lucas T Jae; Lara M Kleinfelter; Megan M Slough; Sarah L Barker; Pablo Guardado-Calvo; Gleyder Román-Sosa; M Eugenia Dieterle; Ana I Kuehne; Nicolás A Muena; Ariel S Wirchnianski; Elisabeth K Nyakatura; J Maximilian Fels; Melinda Ng; Eva Mittler; James Pan; Sushma Bharrhan; Anna Z Wec; Jonathan R Lai; Sachdev S Sidhu; Nicole D Tischler; Félix A Rey; Jason Moffat; Thijn R Brummelkamp; Zhongde Wang; John M Dye; Kartik Chandran
Journal:  Nature       Date:  2018-11-21       Impact factor: 49.962

5.  Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Authors:  R L Brocato; M J Josleyn; V Wahl-Jensen; C S Schmaljohn; J W Hooper
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 6.  New ecological aspects of hantavirus infection: a change of a paradigm and a challenge of prevention--a review.

Authors:  Martin Zeier; Michaela Handermann; Udo Bahr; Baldur Rensch; Sandra Müller; Roland Kehm; Walter Muranyi; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

7.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus.

Authors:  Tobias Manigold; Andrés Mori; Rebecca Graumann; Elena Llop; Valeska Simon; Marcela Ferrés; Francisca Valdivieso; Constanza Castillo; Brian Hjelle; Pablo Vial
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

9.  Stable expression of Hantavirus H8205 strain G1/IL-2 gene and immune protection of the fusion gene.

Authors:  Ying Xiong; Yuan Yuan; Min Jia; Bing Yu; Hanju Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-04

10.  Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.

Authors:  Jay W Hooper; Anthony M Ferro; Victoria Wahl-Jensen
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.